Bristol/Otsuka's Abilify Adds Oral Solution Formulation

The atypical antipsychotic's new formulation will be available in February, the companies say. Abilify is the second drug in the class available as an oral solution, after J&J's Risperdal. Supplemental NDAs for additional Abilify formulations are pending at FDA, Bristol says.